Novel Risk Factors for Atherosclerosis

Athanasia Papazafiropoulou, Nicholas Katsilambros and Nicholas Tentolouris*

Athens University Medical School, 1st Department of Propaedic Medicine, Laiko General Hospital, 17 Ag. Thoma Street, 115 27 Athens, Greece

Abstract: Epidemiologic studies demonstrated that the classical cardiovascular risk factors explain only a part of the increased cardiovascular morbidity and mortality. Large scale studies have shown that novel cardiovascular risk factors, including increased plasma homocysteine, fibrinogen, C-reactive protein, uric acid levels, and increased white blood cells count as well as low adiponectin levels, might have a key role in the pathogenesis of the cardiovascular disease. This review examines recent literature data on the effect of novel risk factors on cardiovascular morbidity and mortality in healthy subjects as well as in subjects at high cardiovascular risk. In addition, the pathogenetic mechanisms linking the effects of the novel risk factors with atherosclerosis are discussed.

Keywords: Cardiovascular disease, risk factors, novel, white blood cells, fibrinogen, uric acid, homocysteine, adiponectin, C-reactive protein.

INTRODUCTION

Despite of the great contribution of the established risk factors to the cardiovascular disease (CVD), they fail to predict all cardiovascular events [1, 2]. A recent analysis of more than 120,000 patients with coronary artery disease (CAD), showed that about 20% of the patients had no evidence of hyperlipidemia, hypertension, diabetes, or smoking, and more than 50% had only one of the above risk factors [1]. Furthermore, another large analysis, with a follow-up for 30 years, showed that 85% to 95% of the subjects with CAD had at least one established risk factor, but so did the subjects without CAD [2].

The above observations have focused the clinical and experimental research over the past decade to the identification and evaluation of novel risk factors, including the number of white blood cell count (WBC), plasma concentrations of fibrinogen, uric acid (UA), homocysteine (Hcy), adiponectin and C-reactive protein (hsCRP). Therefore, the aim of the present review is to provide literature data on the potential relationship between the novel cardiovascular risk factor and CVD and the results of the various studies are summarized in Table I. In addition, the pathogenetic mechanisms linking the effects of the novel risk factors with atherosclerosis are discussed.

WHITE BLOOD CELL COUNT

The WBC count has been associated with CVD since the 1920s [3]. The first study to report a clear relationship between WBC count and cardiovascular morbidity was published in 1974 [4]. This study showed that the WBC count was a strong predictor of myocardial infarction (MI) similar to total serum cholesterol and blood pressure [4]. Later studies reported that subjects with increased WBC count (>9,000 vs. <6,000 mm$^3$ and >10,000 vs. <4,000 mm$^3$) had excess risk of MI [5, 6] and thrombotic strokes [7] independently of gender, smoking habits, blood pressure and cholesterol levels. The multiple risk factor intervention trial (MRFIT) demonstrated also a strong relationship between total WBC count and the risk of CVD [8].

A subanalysis in a cohort of dyslipidemic men from the Helsinki Heart Study of coronary atherosclerosis primary prevention, found that WBC count at baseline was higher in subjects who suffered from acute coronary syndromes than in controls [9]. The above relationship was more profound in smokers with elevated WBC count [9]. In the Hiroshima and Nagasaki Adult Health Study, the WBC count correlated positively with the incidence of CVD in a large population of individuals free of disease at baseline [7]. Recently, a large, retrospective 5-year study showed that high WBC count at baseline correlated with the development of acute coronary syndromes, especially in participants who were free of CVD at baseline (9,209 vs. 6,205/mm$^3$) [10].

Other studies have shown that the relationship between WBC count and CVD exists not only in subjects free of CVD but also in patients with overt CVD even after adjustment for other cardiovascular risk factors. The PARIS-1 study showed that the baseline WBC count was strongly associated with coronary event recurrence and with total mortality 2 to 60 months after MI, even after adjustment for other variables including smoking [11]. Furthermore, it was found that the number of WBC count on admission in patients with acute MI was an independent predictor of early ventricular fibrillation [12]. In a study of patients who have had acute MI within the previous six months, a high WBC count (52,000 vs. 10,600/mm$^3$) was associated with increased risk of re-infarction or death [13]. In the TACTIS-TIMI-18 trial, which included patients with acute coronary syndromes, elevated WBC count at baseline was associated with poorer prognosis, more severe CAD and increased mortality at 6 months [14]. The TIMI-10A and -10B trials found that a relatively high WBC count was associated not only
with new-onset congestive heart failure but also with higher
mortality [15].

The role of total WBC count and WBC subtypes has also
been evaluated in a high-risk population in the CAPRIE trial
[16]. This study showed that an increased neutrophil count
was strongly contributed to the increased cardiovascular risk,
while the impact of monocytes was smaller [16]. In another
large study of patients with or at high risk for CVD, the
neutrophil/lymphocyte ratio was the strongest predictor of
death or MI [17]. In agreement with the previous findings
are the results of a recently published meta-analysis from
seven long-term prospective studies in 30,374 subjects,
which showed that the neutrophil count was the strongest
predictor of CVD [18].

In addition, other studies reported relationships between
CVD and different WBC subtypes. The Hiroshima and Na-
gasaki Adult Health Study showed a positive association
between moderately elevated eosinophil count and CVD [7].
The Paris Prospective Study II [19] showed that the risk of
CVD increased by 1.15 times for an increase of 100
cells/mm³ in monocyte count. In two studies from the United
Kingdom [20], a positive association was found between
neutrophil and eosinophil count and the incidence of CAD.
One retrospective study in patients with CVD [21] showed
that the 5-year survival was significantly better for patients
who had normal in comparison with those who had low lym-
phocyte count.

Several possible pathogenetic mechanisms have been
proposed in order to explain the relationship between ele-
vated WBC and CVD. WBC may influence the development
of CVD through their ability to induce proteolytic and oxida-
tive damage to coronary arteries [22], to promote the release
of inflammatory mediators [23] and to affect blood flow
through the cardiac microvasculature, because WBC are
larger and have stiffer membrane than the red blood cells
and the platelets [24]. Another mechanism that WBC may influ-
ence the development of CVD is by inducing a hypercoagu-
lation state in response to acute MI, since they correlate posi-
tively with plasma fibrinogen and factors VII and VIII levels
[25]. In addition, higher WBC count after acute MI has been
associated with poorer myocardial reperfusion, thrombore-
sistance, and greater thrombus burden [26]. Finally, a study
showed that a high WBC count predicted ventricular fibrilla-
tion in patients with acute MI by affecting the electrical ac-
tivity of the heart [27].

FIBRINOGEN

Fibrinogen is both a coagulation factor and an acute
phase reactant and thus increased plasma fibrinogen levels
may also be a marker of the inflammation associated with
the atherosclerotic process [28]. The ECAT Angina Pectoris
Study showed that higher plasma fibrinogen levels (> 300
mg/dL) resulted in hypercoagulation and thromboembolic
events [29]. Plasma fibrinogen levels are associated with
other risk factors for CVD, such as male sex, obesity [30],
diabetes [31], hypertension [32], high LDL cholesterol and
triglycerides concentrations [33] as well as nephropathy
[34]. Smoking is the strongest known determinant of fi-
brinogen levels in healthy persons [35]. This relationship is
dose-dependent and reversible after smoking cessation [35].

The first study to suggest the role of increased plasma
levels of fibrinogen in CVD was published in the 1980s [36].
It was followed by the results of the Framingham study
which showed that elevated plasma fibrinogen levels were
associated with the classical CVD risk factors [37]. Two
meta-analyses have summarized the results of 18 and 22
prospective studies and have shown a significant and inde-
pendent association between elevated fibrinogen levels and
cardiovascular morbidity and mortality [38, 39].

In patients with CAD, plasma fibrinogen levels are asso-
ciated with the severity of the disease [40] and with higher
risk of re-stenosis after angioplasty [41]. The Northwick
Park Heart Study [42] and the PRIME study [43] demon-
strated that increased baseline levels of fibrinogen were as-
associated with future coronary events compared to normal
fibrinogen levels, even after adjustment for other cardiovas-
cular risk factors. Two prospective studies [44, 45] in sub-
jects with CAD showed a significant relationship between
plasma fibrinogen levels and a second ischemic event as well
as cardiovascular mortality.

Previous data have shown that fibrinogen levels peak
after an acute stroke [46]. Furthermore, elevated plasma fi-
brinogen levels at the time of the stroke are strongly associ-
ated with the recurrence of cardiovascular events within the
next 2 years [47] and with cerebrovascular mortality [48].
The above findings have been confirmed by large studies
which demonstrated the role of fibrinogen in cerebrovascular
disease. The Gothenburg Study [36], the Framingham Study
[37], and the Scottish Heart Study [49], showed a significant
association between fibrinogen levels and cerebrovascular
disease.

Longitudinal data from patients with peripheral arterial
occlusive disease showed that high fibrinogen predicted re-
occlusion of the femoropopliteal vein grafts [50]. Finally, the
Edinburgh Artery Study demonstrated a significant associa-
tion between plasma fibrinogen levels and clinical and sub-
clinical arterial disease [51].

The mechanisms by which fibrinogen may promote athe-
rosclerosis and thrombosis are still not fully understood. Fi-
brinogen promotes atherogenesis by increasing vascular
permeability and collagen synthesis [52], by promoting en-
dotheial injury [53], and by promoting smooth muscle cell
proliferation and migration [53]. Furthermore, it is known that
fibrinogen binds to receptors on the platelet membrane
enhancing their aggregation in vivo [54]. Fibrinogen is also
integrated directly into arteriosclerotic vascular lesions,
where it is converted to fibrinogen degradation products and
binds to low-density lipoproteins [55]. Both fibrinogen and
fibrinogen degradation products stimulate smooth muscle
cell proliferation and migration [55]. These effects suggest
that fibrinogen is involved in the earliest stages of plaque
formation.

URIC ACID

In humans, UA is the end product of purine metabolism
catalysed by the enzyme xanthine oxidoreductase [56]. UA
is degraded in most mammals by urate oxidase (uricase) to
allantoin which is freely excreted in the urine. However,
during the Miocene period, two parallel mutations occurred
in early hominoids that rendered the uricase gene nonfunc-
tional [57]. As a result, humans have higher uric acid levels

The Open Biomarkers Journal, 2008, Volume 1 37
UA levels are higher in postmenopausal women because estrogens have uricosuric effects and in men [60]. Hyperuricemia is common in subjects with obesity, insulin resistance and dyslipidemia because insulin stimulates sodium and urate reabsorption in the proximal tubule [60]. Hyperuricemia predicts the development of CVD in the general population, in subjects with hypertension, and in subjects with preexisting CVD [61]. Hyperuricemia also predicts stroke in diabetic and nondiabetic subjects [62] and predicts the development of hypertension [63] and renal disease in the general population [64].

Existing data regarding the potential role of serum UA to CVD are conflicting. The Framingham study [65] failed to demonstrate any association between serum UA and CVD, while the Chicago Heart Association Detection Project and the NHANES I study found an independent relationship, but this association occurred in women but not in men [66, 67]. In the MONICA Augsburg and Gubbio cohorts, the relationship of UA to MI was suggestive and not significant [68, 69].

On the other hand, the Honolulu Heart study and the Hypertension Detection Follow-up Program study demonstrated a consistent independent relationship between serum UA levels and CVD [70,71]. Another study showed a significant association between serum UA and CAD mortality, which was more profound in women [72]. Furthermore, in low cardiovascular risk populations within the NHANES I follow-up study, UA was an independent predictor of cardiovascular mortality [73].

Serum UA levels are increased in subjects with metabolic syndrome (MS) [74]. Moreover, as the components of MS cluster, there is a parallel rise in plasma UA concentrations [75]. Serum UA levels may also be a reliable predictor of MS in obese youths [76]. Several studies revealed that insulin resistance is the pathogenetic link between elevated serum UA levels and MS [74, 77].

High plasma UA levels are common in subjects with arterial hypertension [78]. The increase in serum UA in hypertension may be due to the decrease in renal blood flow which accompanies the hypertensive state since a low renal blood flow stimulates urate reabsorption [78]. In the Olivetti Heart Study, the baseline serum UA level was the strongest independent predictor of new-onset hypertension and a 1 mg/dL increment in serum UA was associated with a 23% increase in the risk of hypertension during a 12-year follow-up period [62]. Similar were the findings from the Kaiser Permanente Multiphasic Health Checkup study [79]. Two recent epidemiological studies in hypertensive subjects reported a strong, independent association between serum UA at baseline and during therapy and cardiac morbidity and mortality [80, 81]. The Syst-Eur trial was the only study in hypertensive patients that did not find a significant association between serum UA levels and hypertension [82].

Several studies demonstrated an effect of serum UA levels on prediction of stroke and stroke outcomes [62, 83, 84]. One study has shown that serum UA levels predicted independently of other factors the stroke in elderly patients [62]. In patients admitted with stroke, serum UA was an independent predictor of future cardiovascular events in the next 2 years [83]. Furthermore, is has been demonstrated that UA predicted worse early outcome after acute stroke [84]. In diabetic subjects elevated serum UA levels increase the risk of future stroke events [85].

In type 2 diabetic patients elevated plasma UA levels were associated with reduced aortic distensibility, which is considered an index of the total arterial stiffness and an important cardiovascular risk factor [86]. In addition, a recent study found an independent relationship between serum UA and peripheral arterial disease in Asian diabetic patients [87]. In patients with chronic heart failure, a strong relationship was found between elevated serum UA levels and all cause mortality [88].

Medications used for the management of hyperlipidemia and hypertension may reduce plasma UA levels and part of their effect on the reduction of cardiovascular risk is attributable to the reduction in serum UA levels [89, 90]. In the GREACE study [88], an average of 0.8 mg/dL lower serum UA concentrations in the aggressively treated group with statin were associated with lower coronary event rate compared with the control group. In the LIFE study [90], UA levels were associated with the incidence of cardiovascular events independently of other risk factors. Furthermore, the same study showed that a proportion of 29% of the benefit associated with treatment with losartan in terms of cardiovascular risk reduction was attributable to the decreased levels of UA in comparison with the treatment with atenolol [90].

Several possible mechanisms have been proposed in order to explain the association between serum UA levels and CVD. First, there is evidence that increased UA levels promote oxidation of low density lipoprotein cholesterol and facilitate lipid peroxidation [91]. In addition, increased UA levels are associated with increased production of oxygen free radicals [92] which contribute to the initiation and progression of atherosclerosis. Moreover, it has been suggested that elevated UA levels are associated with increased platelet adhesiveness, [93] and this effect could potentiate thrombus formation in patients with acute coronary syndromes. UA has been shown to inhibit nitric oxide (NO) bioavailability [94]. It has been reported that UA infusion in healthy humans resulted in impaired acetylcholine-induced vasodilation in the forearm, thereby documenting impaired endothelial NO release [95]. Finally, UA stimulates rat vascular smooth muscle cell proliferation in vitro [96].

**HOMOCYSTEINE**

Hcy is a sulfur-containing amino acid absent in naturally occurring dietary sources. Hcy levels increase with aging, male gender and in the presence of CVD [97]. An elevated plasma level of Hcy was first suspected to be associated with atherogenic and thrombogenic tendencies in patients with classic homocystinuria. This is a rare autosomal recessive
disease caused by cystathionine b-synthase deficiency and results in high plasma Hcy levels and early onset of atherosclerosis [98].

Several studies reported an association between mild hyperhomocysteinemia and CAD, stroke, and peripheral arterial disease [99, 100]. A meta-analysis [99] of 27 retrospective case-control studies demonstrated that a 5-μmol/L rise in Hcy levels was associated with 1.6- to 1.8-fold increase in the relative risk for CAD, cerebrovascular disease and peripheral vascular disease. A recent meta-analysis of observational studies also suggested that elevated Hcy was a modest independent predictor of ischemic heart disease and stroke in healthy subjects [101].

Previous studies have shown that the risk for MI is higher among subjects with higher plasma Hcy levels than in subjects with normal concentrations of plasma Hcy [102, 103]. In a longitudinal cohort of 1,368 women in Gothenburg, Sweden, after 24-years of follow-up, individuals with high baseline Hcy showed an increased risk for acute MI and mortality from MI compared with individuals with normal Hcy levels [104]. Recent data from the Framingham Heart trial data showed a strong association between Hcy concentrations and the risk for CVD in both men and women with no prior history of CAD [105]. Furthermore, in patients admitted with acute MI, elevated plasma Hcy levels were associated with increased risk of recurrent MI or death [106]. A Norwegian study showed that baseline Hcy levels predicted 10-year mortality in middle aged subjects with MI [107]. Another study including 549 patients with CAD who had at least one vessel disease, plasma Hcy levels predicted nonfatal MI, stent reoclusion and cardiac death after successful coronary angioplasty in the next year [108].

However, other prospective studies have shown conflicting results regarding the relationship between plasma Hcy levels and CVD. The Physicians’ Health Study showed that higher plasma Hcy concentrations were not associated with higher risk of CAD, angina pectoris, and stroke [109]. Additionally, the Multiple Risk Factor Intervention Trial cohort [110], the Atherosclerosis Risk in Communities Study cohort [111] and the North Karelia Project [112] failed to show significant associations between elevated Hcy levels and the risk of major coronary events or stroke.

Several potential mechanisms have been proposed on the potential role of Hcy in CVD, including impairment of endothelial function [113], oxidation of low-density lipoproteins [114], increased monocyte adhesion to the arterial wall [115], increased lipid uptake and retention [115], activation of the inflammatory pathway [115], stimulatory effects on smooth-muscle proliferation [115], and thrombotic tendency mediated by activation of coagulation factors [113] and platelet dysfunction [116].

Homocysteine can be lowered by supplementation with folate, vitamin B6, and B12 [117]. In patients with markedly increased homocysteine levels, vitamin treatment was associated with a decrease in CVD risk in a controlled trial [118]. However, the results of 4 large randomized controlled trials in high-risk patients failed to provide conclusive evidence for a benefit of Hcy lowering on major cardiovascular events. The Vitamin Intervention for Stroke Prevention [119] study showed that treatment with high dose of vitamin B had no effect on recurrent stroke, coronary events or deaths. The Norwegian Vitamin Trial [120] showed that treatment with folic acid decreased Hcy levels by about 27% but had no impact on the composite primary endpoint of MI, stroke and sudden cardiac death. The Heart Outcomes Prevention Evaluation-2 trial [121] showed that reduction of homocysteine had no effect on the primary outcome of the study which was the composite of cardiovascular death, MI and stroke. Finally the Women’s Antioxidant and Folic Acid Cardiovascular Study [122] reported no cardiovascular benefits for the combined folic acid and vitamins B6 and B12 supplementation administered for an average of 7.4 years in 5,442 middle-aged women who had preexisting CVD or at least three cardiovascular risk factors, in spite of a reduction in plasma Hcy levels by an average of about 18%.

ADIPONECTIN

Adiponectin is an adipocytokine with important metabolic effects [123]. It is derived only from adipose tissue and is abundantly present in circulating blood [123]. Plasma levels of adiponectin are lower in obese patients [124], in patients with type 2 diabetes [125] and in patients with CAD [126]. A significant negative relationship exists between body mass index and plasma adiponectin levels [127]. Also, plasma adiponectin concentrations are negatively associated with the total body fat, waist-to-hip ratio and intra-abdominal fat [128].

Prospective studies in adults have consistently shown that low serum adiponectin concentrations predict development of type 2 diabetes mellitus [129-131]. Moreover, hypoadiponectinemia is a marker for predisposition to hypertension in men [132]. Patients with hypertension have significantly lower plasma adiponectin levels than the normotensive counterparts [133]. One study found increased plasma adiponectin concentrations in hypertensive men with renal dysfunction but not in women [134]. Another study found [135] that young Japanese men with high-normal blood pressure had lower adiponectin levels.

Previous data have shown lower adiponectin levels in patients with CAD in comparison with matched controls [126]. In addition, high plasma adiponectin levels protect from MI [136]. A recent study reported that low plasma adiponectin levels were independently associated with CAD even after adjustment for several risk factors [relative risk: 0.75 (95% confidence intervals: 0.39-1.42) for adiponectin levels lower than 7.0 μg/mL] [137]. Cross-sectional studies have shown that serum adiponectin levels are lower in patients with cerebral [138] and peripheral arterial disease [139], as well as in men with CAD [140]. In prospective studies, high adiponectin levels protect from CAD both in subjects with and without diabetes [141]. However, an association between plasma adiponectin concentrations and the risk of CAD could not be demonstrated in three studies: the Strong Heart Study [129], the British Women’s Heart Health Study [142] and a large study in British men with coronary heart disease [143].

In a nested case-control study, plasma adiponectin levels were not associated with future risk of stroke [144]. However, patients with ischaemic stroke had lower plasma levels of adiponectin than controls [138]. Furthermore, low adiponectin levels are associated with poor outcome after first-
event ischemic stroke independently of other factors [145]. Interestingly, in patients with heart failure, plasma levels of adiponectin increase as a function of the severity of the disease (NYHA class) and reduction in body fatness [146]. Thus, in subjects with heart failure, higher adiponectin levels predict mortality independently of other risk factors [147].

In a large Austrian study of healthy middle-aged men and women, serum adiponectin levels were associated inversely with the carotid artery intima-media thickness (IMT) even after adjustment for other cardiovascular risk factors [148]. The negative relationship between adiponectin and IMT was also seen in obese and non-obese children as well as in adolescents [149] and in a study of Swedish men who had a family history of diabetes, whereas no such association was found in the control group [150].

High sensitivity C-reactive protein (hsCRP) is a risk factor for CAD. A significant inverse association was observed between CRP and adiponectin mRNA levels in subcutaneous adipose tissue in humans with atherosclerosis [151]. Circulating adiponectin concentrations are also related to lipid metabolism as indicated by the negative relationship between plasma adiponectin concentrations and plasma concentrations of triglycerides and LDL-cholesterol, and the positive association between circulating adiponectin and fat oxidation as well as HDL-cholesterol levels [152]. In addition, low adiponectin levels have been associated with endothelial dysfunction in the coronary arteries [153] and with the severity of the CAD [154].

Adiponectin influences various aspects of endothelial function. Thus, adiponectin inhibits TNFα-induced expression of VCAM-1, ICAM-1, and E-selectin in human aortic endothelial cells in vitro [125]. Moreover, TNFα-stimulated adhesion of monocytes on endothelial cells is inhibited by adiponectin [125]. Importantly, adiponectin directly stimulates NO production in human and bovine aortic endothelial cells [155]. Apoptosis of human endothelial cells is also suppressed by adiponectin [156]. These functions of adiponectin explain its role in the process of atherosclerosis.

C-REACTIVE PROTEIN

C-reactive protein (CRP), an acute-phase reactant, is synthesized in the liver in response to interleukin-6 [157]. CRP is a marker of vascular inflammation and plays an active role in atherogenesis [157]. A number of large, prospective epidemiologic studies demonstrated that hsCRP is a strong independent predictor of future cardiovascular events, including MI, ischemic stroke, peripheral vascular disease, and sudden cardiac death in individuals without CVD [158]. Thus, the American Heart Association has published a statement suggesting that subjects with CRP levels <1 mg/L to be considered as low-risk, 1 to 3 mg/L as average risk, and >3 mg/L as high-risk for CVD [159].

In the Physicians' Health Study, subjects with high baseline levels of hsCRP had a 2-fold increase in the risk of ischemic stroke or peripheral vascular disease and a 3-fold increase in the risk of MI in comparison with subjects with low hsCRP levels [160]. The Honolulu Heart Program showed that the hsCRP levels were associated with coronary events that occurred as many as 15 years later and that the risk of MI increased in parallel with increasing hsCRP levels [161]. In the primary prevention Women's Health Study, women with the highest baseline hsCRP levels had a 5-fold higher risk of suffering from vascular events and a 7-fold higher risk of MI or stroke than women with low hsCRP levels (≥7.3 vs. ≤1.5 mg/L) [162]. The Nurses' Health Study and the Health Professionals Follow-up Study confirmed the results of the Women's Health Study and showed that the hsCRP was an independent predictor of CVD (≥3.0 vs. ≤1 mg/L) [163]. The Honolulu Heart Program showed a positive association between hsCRP levels and risk of stroke over a follow-up period of 20 years [164]. Analysis of data from the Framingham Heart Study showed also an association between hsCRP levels and stroke [165].

Increased hsCRP concentrations have been shown to be a strong predictor of future cardiovascular risk in patients with established CVD. In the Scandinavian Simvastatin Survival Study, elevated hsCRP levels predicted mortality in patients with stable ischemic heart disease [166]. A meta-analysis of 14 prospective long-term studies on the relationship between hsCRP and the risk of nonfatal MI or CVD death demonstrated an increased relative risk for individuals with increased baseline hsCRP levels in comparison with those with lower hsCRP levels [167].

Other studies have shown variable results. The Multiple Risk Factor Interventional Trial found that increased hsCRP levels predicted increased risk of cardiovascular disease in middle-aged men, but that the relationship was statistically significant only for smokers [168]. Another study found that the association between hsCRP levels and development of future ischemic heart disease was abolished after adjusting for other known risk factors [169].

Obesity is associated with elevated hsCRP [170]. HsCRP levels are also associated with increased blood pressure and are predictive of the development of hypertension [171]. High levels of hsCRP have been shown to be an independent predictor of cardiovascular risk for all degrees of severity of the MS [172]. In a cohort of the Women's Health Study, women who had plasma concentrations in the upper quartile had an increased relative risk of diabetes, even after adjusting for body mass index, family history of diabetes mellitus and smoking, in comparison with the women who had plasma concentrations of hsCRP in the lowest quartile [173]. Similarly, the West of Scotland Coronary Prevention Study indicated that high hsCRP levels are an independent predictor of type 2 diabetes mellitus in healthy middle-aged men [174].

Experimental data have shown that CRP influence vascular vulnerability directly by a variety of mechanisms. Endothelial dysfunction is associated in epidemiologic studies with CRP production [175] and CRP exerts direct effects on the endothelial NO synthesis [176]. Expression of adhesion molecules in endothelial cell cultures is also increased by in vitro exposure to CRP [177]. The expression and activity of plasminogen activator inhibitor-1 by human aortic endothelial cells is upregulated by CRP [178]. Another mechanism by which CRP contributes to CVD is the complement activation as CRP is able to activate the classical route of complement activation [179]. CRP also appears to be involved in the recruitment of monocytes, the infiltration of monocytes into the vessel wall and the subsequent formation of the foam cells. CRP is deposited in the vessel wall at sites of atherogenesis [180] and has been shown to be chemotactic for freshly isolated human blood monocytes [181].
Table 1.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Ref.</th>
<th>Sample Size</th>
<th>Population</th>
<th>Setting</th>
<th>Gender</th>
<th>Follow-up (yrs)</th>
<th>Cut-off Values</th>
<th>Clinical end-Points</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>[5]</td>
<td>7,206</td>
<td>Healthy subjects</td>
<td>France</td>
<td>M</td>
<td>6.5</td>
<td>&lt;6,000 vs. ≥9,000/mm$^3$</td>
<td>Fatal/nonfatal MI</td>
<td>4.5</td>
<td>2.5-7.8</td>
</tr>
<tr>
<td></td>
<td>[6]</td>
<td>15,909</td>
<td>Healthy subjects</td>
<td>U.S.</td>
<td>M/F</td>
<td>16</td>
<td>&lt;4,000 vs. &gt;10,000/mm$^3$</td>
<td>Angina, MI, CHD death</td>
<td>1.82</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[9]</td>
<td>420</td>
<td>Healthy subjects</td>
<td>Finland</td>
<td>M/F</td>
<td>5</td>
<td>NA</td>
<td>CHD incidence</td>
<td>1.13</td>
<td>1.00-1.27</td>
</tr>
<tr>
<td></td>
<td>[10]</td>
<td>6,021</td>
<td>Healthy subjects</td>
<td>Japan</td>
<td>M/F</td>
<td>NA</td>
<td>9,209 vs. 6,205/mm$^3$</td>
<td>ACS incidence</td>
<td>0.038</td>
<td>1.042-4.016</td>
</tr>
<tr>
<td></td>
<td>[13]</td>
<td>1,294</td>
<td>Subjects with acute MI or unstable angina</td>
<td>U.S./Canada</td>
<td>M/F</td>
<td>2.1</td>
<td>52,000 vs. 10,600/mm$^3$</td>
<td>CHD death</td>
<td>1.18</td>
<td>1.00-1.40</td>
</tr>
<tr>
<td></td>
<td>[15]</td>
<td>975</td>
<td>Subjects with acute MI or unstable angina</td>
<td>U.S.</td>
<td>M/F</td>
<td>NA</td>
<td>NA</td>
<td>Death/CHF/shock</td>
<td>0.24 (death)</td>
<td>0.07-0.75</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>[29]</td>
<td>2,700</td>
<td>Subjects with angina</td>
<td>Europe</td>
<td>M/F</td>
<td>2.0</td>
<td>300 vs 328 mg/dL</td>
<td>coronary event</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[36]</td>
<td>792</td>
<td>Healthy Subjects</td>
<td>Sweden</td>
<td>M</td>
<td>13.5</td>
<td>330 vs 360 mg/dL</td>
<td>CVD event</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[37]</td>
<td>554,761</td>
<td>Healthy subjects</td>
<td>U.S.</td>
<td>M/F</td>
<td>12</td>
<td>291.4 mg/dL</td>
<td>CVD event</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[51]</td>
<td>617</td>
<td>Intermittent claudication</td>
<td>Scotland</td>
<td>M/F</td>
<td>1.0</td>
<td>NA</td>
<td>Coronary death</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[43]</td>
<td>9,489</td>
<td>Healthy subjects</td>
<td>France Ireland</td>
<td>M</td>
<td>5</td>
<td>NA</td>
<td>MI</td>
<td>1.56</td>
<td>1.29-1.95</td>
</tr>
<tr>
<td>Uric Acid</td>
<td>[68]</td>
<td>1,044</td>
<td>Healthy subjects</td>
<td>Germany</td>
<td>M/F</td>
<td>8</td>
<td>≥0.373 mmol/L</td>
<td>All cause mortality</td>
<td>2.8</td>
<td>1.6-5.0</td>
</tr>
<tr>
<td></td>
<td>[73]</td>
<td>5,926</td>
<td>Healthy subjects</td>
<td>U.S.</td>
<td>M/F</td>
<td>16</td>
<td>&gt;0.416/0.333 mmol/L</td>
<td>CVD mortality</td>
<td>2.2</td>
<td>1.0-2.99</td>
</tr>
<tr>
<td></td>
<td>[61]</td>
<td>13, 504</td>
<td>Healthy subjects</td>
<td>U.S.</td>
<td>M/F</td>
<td>8</td>
<td>&gt;0.447/0.369 mmol/L</td>
<td>CHD events</td>
<td>M: 1.02</td>
<td>0.69-1.51</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>W: 1.18</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[72]</td>
<td>9,701</td>
<td>Healthy subjects</td>
<td>Belgium</td>
<td>M/F</td>
<td>10</td>
<td>NA</td>
<td>A. CV mortality</td>
<td>M: 1.58</td>
<td>1.10-2.28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>B. CHD mortality</td>
<td>F: 1.67</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[69]</td>
<td>2,469</td>
<td>Healthy subjects</td>
<td>Italy</td>
<td>M/F</td>
<td>6</td>
<td>&gt;0.428 mmol/L</td>
<td>CHD events</td>
<td>1.15</td>
<td>0.94-1.40</td>
</tr>
<tr>
<td></td>
<td>[62]</td>
<td>3,282</td>
<td>Elderly subjects</td>
<td>Italy</td>
<td>M/F</td>
<td>14</td>
<td>&gt;0.38 mmol/L</td>
<td>Stroke mortality</td>
<td>1.61</td>
<td>1.14-2.10</td>
</tr>
<tr>
<td></td>
<td>[85]</td>
<td>1,017</td>
<td>NIDDM subjects</td>
<td>Finland</td>
<td>M/F</td>
<td>7</td>
<td>&gt;0.295 mmol/L</td>
<td>Stroke events</td>
<td>1.91</td>
<td>1.24-2.94</td>
</tr>
<tr>
<td></td>
<td>[83]</td>
<td>3,731</td>
<td>Subjects with stroke</td>
<td>U.K.</td>
<td>M/F</td>
<td>2.7</td>
<td>&gt;0.38 mmol/L on admission</td>
<td>Subsequent events</td>
<td>1.27</td>
<td>1.08-1.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>90-day placement</td>
<td>0.78</td>
<td></td>
</tr>
<tr>
<td>Homocysteine</td>
<td>[103]</td>
<td>791</td>
<td>Past history of CVD</td>
<td>U.S.</td>
<td>F</td>
<td>3</td>
<td>per 5-μmol/L tHcy increment</td>
<td>Fatal and non-fatal CHD</td>
<td>1.74</td>
<td>1.13-2.64</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In conclusion, there is abundant evidence today from observational, experimental and epidemiological studies that novel risk factors of atherosclerosis exist which exert their effects on the arteries either in combination with or above and beyond the classical risk factors. In the novel risk factors are included the number of the WBC count, higher plasma concentrations of fibrinogen, UA, homocysteine and CRP and lower plasma levels of adiponectin. However, there are limited data to suggest that interventions aiming at modification of the novel risk factors reduce CVD morbidity and mortality and further prospective studies are needed to address this issue.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Ref.</th>
<th>Sample Size</th>
<th>Population Setting</th>
<th>Gender</th>
<th>Follow-up (yrs)</th>
<th>Cut-off Values</th>
<th>Clinical endpoints</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>[110] Past history of morbidity (not explained)</td>
<td>712</td>
<td>U.S. M</td>
<td>11</td>
<td>per 5 μmol/L tHcy increment</td>
<td>Non-fatal MI, fatal CHD</td>
<td>0.98</td>
<td>0.83-1.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[111] Past history of CHD, stroke, or TIA</td>
<td>NA</td>
<td>U.S. M/F</td>
<td>3.3</td>
<td>per 5 μmol/L tHcy increment</td>
<td>Fatal and non-fatal CHD</td>
<td>1.15</td>
<td>0.68-1.92</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[112] Past history of CVD</td>
<td>7,424</td>
<td>Finland M/F</td>
<td>9</td>
<td>per 5 μmol/L tHcy increment</td>
<td>Fatal and non-fatal MI</td>
<td>1.03</td>
<td>0.66-1.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[104] Subjects free of previous MI</td>
<td>1,368</td>
<td>Sweden F</td>
<td>32</td>
<td>NA</td>
<td>MI</td>
<td>1.86</td>
<td>5.14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[105] Subjects free of CHF</td>
<td>2,491</td>
<td>U.S. M/F</td>
<td>1979-82 1986-90</td>
<td>NA</td>
<td>CHF</td>
<td>1.84</td>
<td>1.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adiponectin</td>
<td>[142]</td>
<td>4,286</td>
<td>Women free of CAD</td>
<td>U.K. F</td>
<td>4</td>
<td>NA</td>
<td>CAD</td>
<td>0.93</td>
<td>0.78-1.11</td>
</tr>
<tr>
<td>[137]</td>
<td>225</td>
<td>Japan M</td>
<td>-</td>
<td>&lt;4.0 μg/mL</td>
<td>CAD</td>
<td>2.05</td>
<td>1.22</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>[145]</td>
<td>160</td>
<td>Greece M/F</td>
<td>5</td>
<td>&lt;4 μg/mL</td>
<td>Death</td>
<td>5.2</td>
<td>2.1-18.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[147]</td>
<td>195</td>
<td>Denmark M/F</td>
<td>2.6</td>
<td>≤11.6 vs &gt;19.8 μg/mL</td>
<td>Death</td>
<td>3.23</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[129]</td>
<td>4,549</td>
<td>U.S. M/F</td>
<td>11</td>
<td>NA</td>
<td>CHF</td>
<td>0.97</td>
<td>0.81 - 1.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[136]</td>
<td>18 225</td>
<td>U.S. M</td>
<td>6</td>
<td>NA</td>
<td>nonfatal MI</td>
<td>0.39</td>
<td>0.23-0.64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[143]</td>
<td>5661</td>
<td>U.S. M/F</td>
<td>4</td>
<td>&lt;8.32 vs ≥13.33 μg/mL</td>
<td>CHD</td>
<td>0.76</td>
<td>0.59 - 0.98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>[162]</td>
<td>122</td>
<td>Healthy Subjects</td>
<td>U.S. M/F</td>
<td>3</td>
<td>≥7.3 vs ≤1.5 mg/L</td>
<td>CVD event</td>
<td>4.80</td>
<td>2.3-10.1</td>
</tr>
<tr>
<td>[163]</td>
<td>504</td>
<td>Healthy subjects</td>
<td>U.K. M/F</td>
<td>6-8</td>
<td>≥3.0 vs ≤1 mg/L</td>
<td>CAD</td>
<td>1.79</td>
<td>1.27-2.51</td>
<td></td>
</tr>
<tr>
<td>[165]</td>
<td>1,462</td>
<td>Healthy subjects</td>
<td>U.S. M/F</td>
<td>12-14</td>
<td>NA</td>
<td>Ischemic strokes M: 2.0 W: 2.9</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[166]</td>
<td>-</td>
<td>129 who died / 129 matched participants</td>
<td>Italy M/F</td>
<td>5</td>
<td>NA</td>
<td>CAD</td>
<td>2.36</td>
<td>1.06-5.26</td>
<td></td>
</tr>
<tr>
<td>[168]</td>
<td>-</td>
<td>98 MI cases /148 CAD deaths / 491 controls</td>
<td>U.S. M/F</td>
<td>17</td>
<td>&gt; 3.3 vs &lt;1.2 mg/dL</td>
<td>CAD mortality</td>
<td>4.30</td>
<td>1.74-10.8</td>
<td></td>
</tr>
<tr>
<td>[164]</td>
<td>8,006</td>
<td>Healthy subjects</td>
<td>Japan M</td>
<td>20</td>
<td>NA</td>
<td>Stroke</td>
<td>2.5</td>
<td>1.2 - 5.1</td>
<td></td>
</tr>
<tr>
<td>[174]</td>
<td>5,974</td>
<td>Non diabetics</td>
<td>U.K. M/F</td>
<td>5</td>
<td>NA</td>
<td>Diabetes</td>
<td>1.30</td>
<td>1.07-1.58</td>
<td></td>
</tr>
<tr>
<td>[173]</td>
<td>27,628</td>
<td>Healthy subjects</td>
<td>U.S. F</td>
<td>4</td>
<td>≤0.14 vs &gt; 0.48 mg/dL</td>
<td>Diabetes</td>
<td>4.2</td>
<td>1.5 - 12.0</td>
<td></td>
</tr>
</tbody>
</table>

REFERENCES


Parhasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917: 337-40.


Albert C. A randomized trial of folic acid and B-vitamins in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant and Folic Acid Cardiovascular Study. Late-Breaking Clinical Trials I. American Heart Association Scientific Sessions; Chicago, Illinois, 2006.


Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971-6.


